Lucira Stock Analysis

LHDX -  USA Stock  

USD 4.99  0.31  5.85%

The current indifference towards the small price fluctuations of Lucira Health may encourage investors to take a closer look at the firm as it is trading at a share price of 4.99 on 245,142 in trading volume. The company directors and management did not add any value to Lucira Health investors in December. However, most investors can still diversify their portfolios with Lucira Health to hedge their inherited risk against high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 7.08. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Lucira Health partners.
Additionally, see Stocks Correlation.

Lucira Stock Analysis 

 
Refresh
The Lucira Health stock analysis report makes it easy to digest most publicly released information about Lucira Health and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Lucira Stock analysis module also helps to analyze the Lucira Health price relationship with some important fundamental indicators such as market cap and management efficiency.

Lucira Stock Analysis Notes

About 61.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.07. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Lucira Health recorded a loss per share of 2.89. The entity had not issued any dividends in recent years. Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California. Lucira Health operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 102 people. To find out more about Lucira Health contact the company at 510 350 8071 or learn more at https://www.lucirahealth.com.

Lucira Health Quarterly Cost of Revenue

16.46 MillionShare

Lucira Health Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Lucira Health's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Lucira Health or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Lucira Health has very high historical volatility over the last 90 days
The company reported the previous year's revenue of 32.2 M. Net Loss for the year was (74.2 M) with loss before overhead, payroll, taxes, and interest of (1.67 M).
Lucira Health currently holds about 117.29 M in cash with (107.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.99.
Lucira Health has a frail financial position based on the latest SEC disclosures
Roughly 61.0% of the company shares are owned by institutional investors
Latest headline from people.com: 7 FDA-Authorized At-Home COVID-19 Tests You Can Buy Online PEOPLE.com - PEOPLE.com

Lucira Health Upcoming and Recent Events

Earnings reports are used by Lucira Health to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Lucira Health previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report30th of March 2022
Next Earnings Report12th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End30th of March 2022
Last Quarter Report30th of September 2021
Last Earning Announcement31st of December 2020

Lucira Largest EPS Surprises

Earnings surprises can significantly impact Lucira Health's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2021-08-12
2021-06-30-0.32-0.3812-0.061219 
2021-11-11
2021-09-30-0.54-0.47310.066912 
2021-05-13
2021-03-31-0.33-0.58-0.2575 
View All Earnings Estimates

Lucira Health SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Lucira Health prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Lucira Health investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Lucira Health specific information freely available to individual and institutional investors to make a timely investment decision.
10th of January 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
29th of December 2021
Financial Statements and Exhibits. Regulation FD Disclosure
View
23rd of December 2021
Regulation FD Disclosure
View
22nd of December 2021
Financial Statements and Exhibits. Regulation FD Disclosure. Entry into a Material Definitive Agreement
View
21st of December 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
12th of November 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
8th of October 2021
Financial Statements and Exhibits. Regulation FD Disclosure
View
20th of September 2021
Financial Statements and Exhibits. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View

Lucira Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Lucira Health is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Lucira Health backward and forwards among themselves. Lucira Health's institutional investor refers to the entity that pools money to purchase Lucira Health's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Epiq Capital Group LlcCommon Shares13.8 M104.9 M
Pura Vida Investments LlcCommon SharesM7.6 M
Bioimpact Capital LlcCommon Shares578.1 K4.4 M
Vanguard Group IncCommon Shares448.5 K3.4 M
Millennium Management LlcCommon Shares221 K1.7 M
Silverarc Capital Management LlcCommon Shares220.8 K1.7 M
Board Of Trustees Of The Leland Stanford Junior UniversityCommon Shares124.5 K946 K
Group One Trading LpCall Options59.1 K449 K
Note, although Lucira Health's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Lucira Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 207.89 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Lucira Health's market, we take the total number of its shares issued and multiply it by Lucira Health's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Lucira Profitablity

Lucira Health's profitability indicators refer to fundamental financial ratios that showcase Lucira Health's ability to generate income relative to its revenue or operating costs. If, let's say, Lucira Health is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Lucira Health's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Lucira Health's profitability requires more research than a typical breakdown of Lucira Health's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (230.43) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (211.5) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -2.12.
Last ReportedProjected for 2022
Return on Average Assets(0.86) (0.93) 
Return on Average Equity 0.98  0.87 
Return on Invested Capital(1.65) (1.78) 
Return on Sales(124.78) (134.63) 

Management Efficiency

The entity has return on total asset (ROA) of (27.89) % which means that it has lost $27.89 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (55.03) %, meaning that it created substantial loss on money invested by shareholders. Lucira Health management efficiency ratios could be used to measure how well lucira health manages its routine affairs as well as how well it operates its assets and liabilities. Return on Average Assets is likely to drop to -0.93 in 2022. Return on Average Equity is likely to drop to 0.87 in 2022. Lucira Health Total Assets are fairly stable at the moment as compared to the past year. Lucira Health reported Total Assets of 106.61 Million in 2021. Current Assets is likely to rise to about 87.1 M in 2022, whereas Asset Turnover is likely to drop 0.004474 in 2022.
Last ReportedProjected for 2022
Book Value per Share(23.40) (24.02) 
Tangible Assets Book Value per Share 44.48  47.99 
Tangible Asset Value106.6 M115 M

Technical Drivers

As of the 21st of January, Lucira Health secures the Downside Deviation of 6.02, mean deviation of 5.07, and Risk Adjusted Performance of 0.0201. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Lucira Health, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to break down nineteen technical drivers for Lucira Health, which can be compared to its peers in the industry. Please verify Lucira Health variance, as well as the relationship between the value at risk and skewness to decide if Lucira Health is priced some-what accurately, providing market reflects its recent price of 4.99 per share. Given that Lucira Health has jensen alpha of 0.0493, we recommend you to check Lucira Health's last-minute market performance to make sure the company can sustain itself at a future point.

Lucira Health Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Triple Exponential Moving Average (T3) indicator is developed by Tim Tillson as Lucira Health price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average. View also all equity analysis or get more info about triple exponential moving average t3 overlap studies indicator.

Lucira Health Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Lucira Health insiders, such as employees or executives, is commonly permitted as long as it does not rely on Lucira Health's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Lucira Health insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Lucira Health Predictive Daily Indicators

Lucira Health intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Lucira Health stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Lucira Health Forecast Models

Lucira Health time-series forecasting models is one of many Lucira Health's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Lucira Health's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Lucira Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Lucira Health stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Lucira shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Lucira Health. By using and applying Lucira Stock analysis, traders can create a robust methodology for identifying Lucira entry and exit points for their positions.
Last ReportedProjected for 2022
Gross Margin(5.59) (6.03) 
Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California. Lucira Health operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 102 people.

Current Lucira Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Lucira analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Lucira analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
8.0Sell2Odds
Lucira Health current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Lucira analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Lucira stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Lucira Health, talking to its executives and customers, or listening to Lucira conference calls.
Lucira Analyst Advice Details

Lucira Stock Analysis Indicators

Lucira Health stock analysis indicators help investors evaluate how Lucira Health stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Lucira Health shares will generate the highest return on investment. By understating and applying Lucira Health stock analysis, traders can identify Lucira Health position entry and exit signals to maximize returns.
Quick Ratio5.06
Fifty Two Week Low4.23
Shares Short Prior Month791.11k
Average Daily Volume Last 10 Day221.67k
Average Daily Volume In Three Month294.11k
Shares Percent Shares Out2.19%
Gross Margins-7.61%
Short Percent Of Float5.17%
Forward Price Earnings-4.49
Float Shares29.33M
Fifty Two Week High37.99
Enterprise Value To Ebitda-2.83
Fifty Day Average6.78
Two Hundred Day Average7.00
Enterprise Value To Revenue5.79
Additionally, see Stocks Correlation. Note that the Lucira Health information on this page should be used as a complementary analysis to other Lucira Health's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Complementary Tools for Lucira Stock analysis

When running Lucira Health price analysis, check to measure Lucira Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lucira Health is operating at the current time. Most of Lucira Health's value examination focuses on studying past and present price action to predict the probability of Lucira Health's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Lucira Health's price. Additionally, you may evaluate how the addition of Lucira Health to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Is Lucira Health's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lucira Health. If investors know Lucira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lucira Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Lucira Health is measured differently than its book value, which is the value of Lucira that is recorded on the company's balance sheet. Investors also form their own opinion of Lucira Health's value that differs from its market value or its book value, called intrinsic value, which is Lucira Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lucira Health's market value can be influenced by many factors that don't directly affect Lucira Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lucira Health's value and its price as these two are different measures arrived at by different means. Investors typically determine Lucira Health value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lucira Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.